fluvoxamine as a mRNA inhibitor via S1 receptor

 

Fluvoxamine

Last Updated: April 23, 2021

Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) that is approved by the Food and Drug Administration (FDA) for the treatment of obsessive-compulsive disorder and is used for other conditions, including depression.

 source NIH website click

 Medical journal and efficacy via S1 receptor binding

"Detailed mechanisms of action of fluvoxamine for COVID-19 are currently unknown. In 1996, we reported that fluvoxamine binds to endoplasmic reticulum (ER) protein sigma-1 receptor with high affinity, suggesting a role of sigma-1 receptor in the mechanisms of its action"   

 source Medical journal
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8412866/

 

 Jimmy Dore in the US was given fluvoxamine for long covid symptoms.

see Jimmy Dore youtube.

 

Dr Been explains fluvoxamine

https://youtu.be/3CfRw0zYzlg